Natural Experiments to Understand Plan and Provider Behavior in an Era of Accountability
了解责任时代的计划和提供者行为的自然实验
基本信息
- 批准号:10616700
- 负责人:
- 金额:$ 33.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-04-15 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:AccountabilityAcuteAffectAgeAreaCaringCoinsuranceCompetitive BiddingContractsCountyDataData SourcesDisabled PersonsElderlyEnrollmentEvaluationEvolutionFee-for-Service PlansGoalsHealthHealth PromotionHealth care facilityHeterogeneityHospitalsIncentivesLength of StayLinkManaged CareMeasurementMeasuresMedicaidMedicareMethodologyMethodsModelingMonitorNatural experimentNatureOutcomeOutcome MeasurePatient CarePatient-Focused OutcomesPatientsPerformancePersonal SatisfactionPhysiciansPopulationPositioning AttributePrivatizationProcessProductionProspective Payment SystemProviderRandomizedResearchResidual stateResourcesRiskRisk AdjustmentRisk AssessmentServicesSkilled Nursing FacilitiesSortingSourceSystemVariantaccountable care organizationacute carebasebeneficiarybundled paymentcare deliverycostdesigndual eligibleexperiencefinancial incentiveflexibilitygeographic differencehealth planhigh rewardimprovedimproved outcomeinsightintrinsic motivationpatient populationpaymentphysical therapistprogramsprovider behaviorresponserisk selectionrisk sharingtoolwasting
项目摘要
ABSTRACT
Payment to providers and plans in Medicare has far-reaching implications for the health of the elderly and
disabled. The fee-for-service basis for payment has been rightly criticized for incentivizing excessive and
potentially harmful provision of care and for interfering with the production of health by linking reimbursement
to specific inputs. To establish greater flexibility and accountability, Medicare has increasingly transferred
financial risk to entities that can manage care—first to private plans in the Medicare Advantage (MA) program
and more recently to providers directly in alternative payment models (APMs) in traditional Medicare (TM). In
both models, additional payment adjustments are tied to performance on quality measures. These approaches
to integrating the financing and delivery of care create opportunities to improve patient care, but empirical
study has been challenging. Evidence on the merits of the MA program and the relative performance of MA
and APMs has been largely observational and limited in analysis of patient experiences and health outcomes.
In addition, risk contracting relies heavily on risk adjustment to profile plan or provider performance and to align
resources with the needs of patient populations, but the adequacy of risk adjustment has not been well
described. This project will make substantial contributions by leveraging natural experiments and new data to
understand plan and provider responses to payment incentives and their implications for patients and payment
system design. The project includes three aims. First, we will use natural experiments to compare performance
between MA and TM and different variants of each system. Sources of quasi-randomization to MA vs. TM will
include differences across state and county borders in MA exposure and transitions from Medicaid to dual
eligibility at age 65 in areas of high or low MA exposure. We will explore effect heterogeneity based on
geographic variation in the configuration of MA (e.g., by plan type) and TM (e.g., by APM activity). Second, we
will assess the marginal value of post-acute care in skilled nursing facilities (SNFs) and effects of incentives to
alter post-acute length of stay on patient outcomes in different payment models, including TM, MA, and APMs.
Post-acute care is an area of intense activity in MA and APMs that offers insights into provider agency.
Approaches will make use of discontinuities in SNF reimbursement and coinsurance related to length of stay
and natural randomization of patients to physical therapists in hospitals. Third, we will determine the extent to
which risk-adjusted MA-TM differences in outcomes reflect performance differences vs. residual risk selection
and assess the adequacy of risk-adjustment methods. We will use strategies from our first aim to compare MA-
TM performance differences in self-sorted vs. quasi-randomized populations. Findings will characterize the
prospects for value-enhancing competition or unintended consequences from prospective payment systems
and will have important implications for the validity of quality scores. Thus, the project will provide foundational
evidence and insights for improving health through payment systems and performance monitoring.
摘要
向医疗保险中的提供者和计划付款对老年人的健康有着深远的影响,
禁用.按服务收费的支付基础受到了正确的批评,因为它鼓励了过度的,
可能有害的护理提供,并通过将报销与医疗费用挂钩,
具体的投入。为了建立更大的灵活性和问责制,医疗保险越来越多地转移到
在Medicare Advantage(MA)计划中,可以管理护理优先到私人计划的实体的财务风险
以及最近在传统Medicare(TM)中的替代支付模型(APM)中直接提供给提供者。在
在这两种模式下,额外的付款调整与质量措施的表现挂钩。这些方法
整合融资和提供护理创造机会,以改善病人护理,但经验
研究是具有挑战性的。关于千年评估方案优点和千年评估相对业绩的证据
和APM在很大程度上是观察性的,在分析患者经历和健康结果方面受到限制。
此外,风险承包在很大程度上依赖于风险调整,以了解计划或提供商的业绩,并与
资源与患者人群的需求,但风险调整的充分性并不好
介绍了该项目将通过利用自然实验和新数据,
了解计划和提供者对支付激励措施的反应及其对患者和支付的影响
系统设计该项目包括三个目标。首先,我们将使用自然实验来比较性能
MA和TM以及每个系统的不同变体之间的差异。MA与TM的准随机化来源将
包括州和县边界之间MA风险的差异以及从医疗补助到双重医疗补助的过渡
在高或低MA暴露地区,65岁的资格。我们将基于以下因素探索效应异质性:
MA配置的地理变化(例如,按计划类型)和TM(例如,APM活动)。二是
将评估熟练护理机构(SNF)中急性期后护理的边际价值以及激励措施的效果,
在不同的支付模式下,包括TM、MA和APM,改变急性期后住院时间对患者结局的影响。
急性期后护理是MA和APM的一个密集活动领域,为提供者代理提供了见解。
方法将利用SNF报销和与停留时间相关的共同保险的不连续性
和自然随机化的病人到医院的物理治疗师。第三,我们将确定
风险调整后的MA-TM结果差异反映了性能差异与剩余风险选择
并评估风险调整方法的适当性。我们将使用第一个目标中的策略来比较MA-
自分类与准随机化人群的TM性能差异。调查结果将描述
增值竞争的前景或预期支付系统的意外后果
并将对质量分数的有效性产生重要影响。因此,该项目将提供基础
通过支付系统和绩效监测改善健康的证据和见解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John Michael McWilliams其他文献
John Michael McWilliams的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John Michael McWilliams', 18)}}的其他基金
Reforming Medicare: Beneficiary Choice, Plan Payment, and Accountable Care
改革医疗保险:受益人选择、计划付款和责任医疗
- 批准号:
8314022 - 财政年份:2010
- 资助金额:
$ 33.88万 - 项目类别:
Reforming Medicare: Beneficiary Choice, Plan Payment, and Accountable Care
改革医疗保险:受益人选择、计划付款和责任医疗
- 批准号:
8143466 - 财政年份:2010
- 资助金额:
$ 33.88万 - 项目类别:
Reforming Medicare: Beneficiary Choice, Plan Payment, and Accountable Care
改革医疗保险:受益人选择、计划付款和责任医疗
- 批准号:
8014617 - 财政年份:2010
- 资助金额:
$ 33.88万 - 项目类别:
Improving Medicare in an Era of Change: Natural experiments to understand protective effects of Medicaid and Medicare policy during the COVID-19 pandemic for populations with a high rates of dementia
在变革时代改善医疗保险:通过自然实验了解 COVID-19 大流行期间医疗补助和医疗保险政策对痴呆症高发人群的保护作用
- 批准号:
10287696 - 财政年份:2009
- 资助金额:
$ 33.88万 - 项目类别:
Natural Experiments to Understand Plan and Provider Behavior in an Era of Accountability
了解责任时代的计划和提供者行为的自然实验
- 批准号:
10196903 - 财政年份:2009
- 资助金额:
$ 33.88万 - 项目类别:
Natural Experiments to Understand Plan and Provider Behavior in an Era of Accountability
了解责任时代的计划和提供者行为的自然实验
- 批准号:
10379882 - 财政年份:2009
- 资助金额:
$ 33.88万 - 项目类别:
Project 3: Effects of ACOs in Medicare on Utilization and Quality: Heterogeneity
项目 3:医疗保险中 ACO 对利用和质量的影响:异质性
- 批准号:
9110084 - 财政年份:
- 资助金额:
$ 33.88万 - 项目类别:
Project 3: Effects of ACOs in Medicare on Utilization and Quality: Heterogeneity
项目 3:医疗保险中 ACO 对利用和质量的影响:异质性
- 批准号:
8793357 - 财政年份:
- 资助金额:
$ 33.88万 - 项目类别:
Project 3: Effects of ACOs in Medicare on Utilization and Quality: Heterogeneity
项目 3:医疗保险中 ACO 对利用和质量的影响:异质性
- 批准号:
9756140 - 财政年份:
- 资助金额:
$ 33.88万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 33.88万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 33.88万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 33.88万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 33.88万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 33.88万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 33.88万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 33.88万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 33.88万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 33.88万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 33.88万 - 项目类别:
Operating Grants














{{item.name}}会员




